Could a 'creative deal' between Perrigo, Amneal help reinvent both struggling businesses?

With a spinoff for its prescription business on the ropes, Perrigo is treading water in its plans to reinvent its flagging business. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?